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     INTRODUCTION 
  Yellow fever (YF) is a viral illness transmitted by mosqui-
toes (  Aedes   and   Haemagogus   genera) infected with the YF 
virus (YFV), which belongs to the genus   Flavivirus   (family 
  Flaviviridae  ). The clinical manifestations of infection vary con-
siderably, ranging from asymptomatic to classic forms of hem-
orrhagic fever, which are associated with high fatality rates.  1  
  At present, the control of urban YFV transmission can be 
accomplished by vector control and vaccination. However, YF 
remains an endemic and epidemic problem affecting millions 
of people in tropical Africa and South America, especially 
those living at the fringe of urban and sylvatic environments. It 
is also a continuing threat to people who travel to these regions 
without vaccination.  2   In Brazil, YF is endemic in extensive 
regions of the Amazon forest and the southwest of the coun-
try; therefore, YF vaccination is strongly recommended for 
travelers to these regions.  3   The boundary between these two 
zones is constantly affected by periodic expansions into areas 
of epizootic activity. YFV is transmitted in sparsely populated 
forested areas and affects mainly individuals engaged in clear-
ing land for agriculture, ecological tourism, and other profes-
sional activities related to penetration of the jungle.  4   From 
1980 to 2008, there were 723 confirmed YF cases of sylvatic 
origin, among which 389 deaths occurred, resulting in a 53.8% 
average lethality. Adult males were the most affected segment 
of the population.  3  
  Because of the presence of a large susceptible human popu-
lation to YFV and the vector   A. aegypti   in the coastal zones 
of the country, the major urban centers of Brazil are vulnera-
ble to the introduction and spread of YFV. Although there has 
been no report of urban transmission of YFV in Brazil since 
1942, this country is still at risk of YFV outbreaks.  4  
  Given the high infestation indices of   A. aegypti   reported 
in several municipalities of the country and the concomitant 
high proportion of non-immune humans, there is a high risk of 
reurbanization of the disease in Brazil. Although   A. albopic-
tus   has been found to be less susceptible to YFV than sev-
eral   A. aegypti   samples tested from Brazil,   A. albopictus   may 
continue to colonize non-urban areas of the country, becom-
ing more abundant in rural areas and endemic and transition 
areas for sylvatic YF at the forest fringes. Thus, this species 
could become a real problem, because it could become a link 
between the jungle and urban cycles of YF.  5–  7  
 Two distinct but related lineages (17D-204 and 17DD) of YF 
vaccine have been developed; these two strains share 99.9% 
nucleic acid sequence homology. The original 17D strain was 
developed after 176 culture passages of the wild-type Asibi 
strain in mouse and chicken tissues. Over 500 million doses 
have been administered since the vaccine was first developed 
in 1937. The substrains 17D-204 and 17DD, which are at pas-
sages 235–240 and 287–289, respectively, are the ones currently 
used for the vaccine. The genomes of the Asibi, 17D-204, and 
17DD viruses have been sequenced, and the wild-type Asibi 
differs from the vaccine viruses by 48 nucleotides encoding 
20 amino acid substitutions.  8   The 17D-213 strain, currently at 
passage 240, is a derivative of 17D-204.  9,  10   The 17D-204 vac-
cine is manufactured in the United States, Switzerland, Russia, 
Senegal, and China; the 17DD vaccine is manufactured and 
used in South America.  8,  11  
  The YF vaccine currently used in Brazil is the 17DD strain, 
which has been produced at the Oswaldo Cruz Institute from 
an attenuated viral strain.  12   In 1942, the seed lot system was 
designed with the goal of reducing the variability of vaccine 
lot production. In this system, a large lot of virus is produced 
and extensively verified for titer, sterility, and viral attenuation 
by assays that include the stringent monkey neurovirulence 
test. Therefore, vaccine batches produced from this lot are at 
the same passage level as other lots produced later, provid-
ing the necessary production standardization.  13   Several stud-
ies have shown the high efficacy (> 95%) of this vaccine in the 
prevention and control of the YF epidemic.  14  
  In response to the increase in epizootic activity and the 
threat of urban YFV transmission in recent years, use of the 
YF vaccine has increased strikingly in Brazil. In addition, 
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a new policy was established in 1998 to include the vaccine in 
the national program of childhood immunization for people 
living in an endemic zone. The minimum recommended age 
for immunization is 9 months. Between 1990 and 2000, about 
85 million doses of YF vaccine were administered across the 
whole country.  15  
  The YF vaccine is considered by some vaccinologists to be 
one of the safest attenuated virus vaccines. Fewer than 25% of 
vaccinees develop mild systemic symptoms, which may include 
headache, myalgia, discomfort at the site of vaccination, or 
low-grade fever from 2 to 6 days after vaccination.  16   Despite 
the strong safety profile of the YF vaccines, reports of rare 
YF vaccine-associated side effects and serious adverse events 
have been described in the literature, including severe aller-
gic reactions, neurotropic adverse disease, and viscerotropic 
disease.  16   In a study published in 2009, YF vaccine-associated 
viscerotropic disease was estimated to occur in approximately 
0.3–0.4 of 100,000 vaccinations, and risk factors identified to 
date include advanced age and a history of thymus disease. 
The incidence of YF vaccine-associated neurotropic disease 
has been estimated to be 0.4–0.8 per 100,000 vaccinations.  17  
  The majority of the antibody kinetics studies that have been 
published are based on data obtained from the 17D strains, 
and according to Monath,  2   protective levels of neutraliz-
ing antibody are found in 90% of recipients within 10 days 
and in 99% within 30 days. Immunity is very durable, prob-
ably providing lifelong protection after a single dose; to be 
conservative, revaccination after 10 years is required under 
International Health Regulations for a valid travel certifi-
cate.  2   In contrast, very few data are available regarding the 
kinetics of the antibody response to the YF-17DD vaccine 
used in Brazil. In addition, some reports continue to suggest 
an increase on the incidence of side effects and deaths related 
to vaccination, mainly in elderly people and children.  2,  15,  18   The 
cause of these rare but severe side effects in some individuals 
is not known.  8   It is postulated that virus mutations and specific 
factors in the host’s genetic background or concomitant dis-
eases are to blame.  1,  19  
  In addition, dengue virus (DENV) and YFV are related 
viruses of the   Flavivirus   genus and share cross-reactive anti-
body epitopes. However, there is still very little understanding 
on how   Flavivirus   cross-reactive immune responses elicited 
by natural dengue infections would modulate the immune 
responses to YF vaccines. It is postulated that the high prev-
alence of anti-dengue antibodies in the Southeast Asia pop-
ulation is the reason for the absence of YFV in this region. 
Some studies have also suggested that the existence of anti-
dengue immune responses could interfere with the response 
to the YF vaccine, and it has been shown that previous expo-
sure to DENV in humans may reduce YF viremia, ameliorate 
the severity of the disease, and reduce the fatality rate without 
decreasing the rate of infection.  20   However, there is no evi-
dence suggesting that pre-exposure to a flavivirus could lead 
to change in the safety profile of YF vaccines. 
  In this study, we have described the development of a YF 
cohort of vaccinated individuals living in Recife, the capital 
of the state of Pernambuco, Brazil, for use in studying the 
immune responses against the YF-17DD and evaluating pos-
sible effects of existing anti-dengue antibodies on the YF vac-
cine responses. In addition, the samples from this cohort have 
also been used to map T-cell epitopes elicited by dengue infec-
tion and YF-17DD vaccine. 
   MATERIALS AND  METHODS 
    Cohort design and study population.    This  prospective 
study was conducted in the city of Recife, Pernambuco, in the 
northeastern region of Brazil. Recife is located in the coastal 
non-endemic YF zone, whereas vaccination against YF is 
recommended only for those traveling to endemic regions 
( Figure  1 ).  Healthy     subjects  ( N   = 260) older than 10 years of 
age who had been immunized for the first time with the YFV-
17DD vaccine (Bio-Manguinhos, Oswaldo Cruz Foundation, 
Rio de Janeiro, Brazil) at the Brazilian National Health 
Surveillance Agency (ANVISA; located at the International 
Airport of Recife) were invited to participate in this study. 
Subjects were enrolled from September 2005 to August 
2009. A questionnaire was administered to each subject, and 
laboratory evaluations were performed before and after 
vaccination. The subjects were followed with blood sample 
collection for a period of 4–5 years. 
    Ethical  considerations.     Written consent was obtained 
from each subject (or his/her guardian) enrolled in the study. 
All data were handled confidentially and anonymously. 
Serological results were shared with each volunteer. This study 
was reviewed and approved by the Ethics Committee of the 
Brazilian Ministry of Health (CONEP 12138). 
   Blood  sample  collection.     From each subject, up to six blood 
samples were collected during the 5-year period of study. 
The first blood sample was collected before vaccination, and 
a second sample was collected approximately 30 days later. 
From then on, blood samples were obtained annually for the 
remainder of the 5-year study. Sequential blood samples were 
obtained from 238 of 260 volunteers enrolled in this cohort 
for a total of 951 samples. Blood samples were collected into 
10-mL Vacutainer tubes. Serum samples were separated and 
stored in cryovials (1 mL per vial) at −20°C for serological 
analyses. Plasma and peripheral blood mononuclear cells 
(PBMCs) were also separated and cryopreserved (−80°C) for 
further studies as previously described.  21   The  cryopreserved 
samples can serve as a useful tool for future immunological 
investigations, such as identification of immunodominant       
human leukocyte antigen (HLA)-restricted T-cell epitopes. 
 Figure 1.        Regions in Brazil where YF vaccination is recommended. 
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   Laboratory  tests.     The first three serum samples collected 
were tested by enzyme immunoassay, immunoglobulin M 
(IgM) antibody-enzyme-linked immunosorbent assay (MAC-
ELISA), and immunoglobulin G (IgG) antibody-enzyme-
linked immunosorbent assay (GAC-ELISA)  22   and by an 
indirect IgG-ELISA  23   to determine levels of IgM and IgG 
before and after YFV immunization. A plaque reduction neu-
tralization test (PRNT) was used to determine the prevalence 
of YFV antibodies and/or seroconversion after YF-17DD 
immunization.  24   Dengue virus, but no other   Flavivirus ,  has 
been detected in Recife, Pernambuco; thus, all serum sam-
ples collected before vaccination were tested for DENV IgG 
antibodies to study the cross-reactivity with YFV. 
   Reference  specimens.     Positive and negative control sera 
used for serological tests were obtained from the Department 
of Virology—Central Laboratory of Public Health (Secretary 
of Health of the State of Pernambuco, Brazil). The YF-positive 
control serum was a pool of 12 serum specimens obtained 
from individuals who did not have anti-dengue antibody and 
had been recently vaccinated with YF-17DD. Negative control 
serum specimens were obtained from individuals who did not 
have anti-DENV or anti-YFV antibodies. 
   YF  antigen.     The YF antigen used in the ELISA tests was 
obtained by the sucrose–acetone method  25   from the brains 
of suckling mice infected with YFV (provided by Dr. Pedro 
Vasconcelos from the Arbovirus Laboratory of the Evandro 
Chagas Institute, Ministry of Health, Brazil), where it is produced 
for distribution to Public Health Laboratories in the country. 
   YFV.     The human YF vaccine composed of attenuated 
YF-17DD was obtained from the Oswaldo Cruz Foundation 
(Rio de Janeiro, Brazil). The vaccine was reconstituted with 
the distilled water provided, kept in an ice bath, and used for 
cell inoculation. Vero (African green monkey kidney) cells 
were grown in minimal essential medium (MEM; Gibco BRL, 
Gaithersburg, MD) supplemented with 10% fetal bovine 
serum (FBS; Gibco BRL) and 1% penicillin/streptomycin 
(Gibco BRL) and kept at 37°C in 5% CO  2 .  Subconfluent Vero 
cells grown in T175 flasks were infected with YF-17DD at a 
multiplicity of infection (moi) of 0.1 for 5–6 days in MEM 
with 2% FBS and incubated at 37°C in 5% CO  2 .  After  freeze-
thawing, the cell suspension was centrifuged at 2,000 rpm 
for 10 min at 4°C. The supernatant containing the YF-17DD 
particles was collected, it was added to 20% FBS, and it was 
stored in vials at −80°C. The YFV strain 17DD was propagated 
in Vero cells at 37°C in 5% CO  2   to a titer of 1.8 × 10  6   plaque-
forming units (PFU) per mL and used in the PRNT test. 
   Anti-DENV  IgG  antibody  detection.    All  serum  samples 
collected before YF vaccination and those found to be 
negative for anti-dengue IgG were tested using the indirect 
ELISA kit for anti-dengue IgG (PanBio, Pty., Ltd., Brisbane, 
QLD, Australia). The assay was performed according to the 
recommended guidelines, and the results were calculated 
and interpreted as negative or positive according to the 
manufacturer’s instructions. 
   Anti-YFV  IgM  antibody  detection.    The  protocol  reported 
by Kuno and others  22   was used for MAC-ELISA with a few 
modifications. In brief, microtiter plates (Nunc-Immuno 
Maxisorp, Langenselbold, HE, Germany) were coated with 
100 μL of a 1:400 dilution of affinity-purified goat anti-human 
IgM (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, 
MD) in carbonate buffer (pH 9.6) and incubated overnight 
at 4°C. The plates were then washed with phosphate-buffered 
saline (PBS; pH 7.4) and blotted dry on paper towels between 
washing steps. After washing, plates were blocked with 200 μL 
PBS containing 4% bovine serum albumin (BSA) fraction 
V (Sigma, St. Louis, MO) and incubated for 1 hour at room 
temperature (RT). After blocking, the plates were washed as 
before. Patient serum (50 μL) diluted 1:50 in PBS/0.5% BSA 
was added, in duplicate, to the microtiter well and incubated 
at 37°C for 1 hour (positive and negative controls sera were 
included). After washing, 50 μL YF antigen diluted 1:32 in 
PBS/0.5% BSA (to yield 16 HA units) were added to each 
microwell and incubated at 37°C for 1 hour. After washing, 25 μL 
horseradish peroxidase conjugate prepared from an anti-
flavivirus monoclonal antibody 6BC1-1 (Centers for Disease 
Control and Prevention [CDC]) diluted 1:13,000 in PBS/0.5% 
BSA was added to each well. After another incubation at 37°C 
for 30 minutes, the plates were washed six times in PBS and 
then incubated with 100 μL freshly prepared substrate solu-
tion 2,2¢-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) 
(ABTS; Microwell Peroxidase Substrate System; Kirkegaard & 
Perry Laboratories, Inc., Gaithersburg, MD) in H  2 0 2   diluted 1:1. 
The reaction was allowed to develop in the dark at RT for 30–60 
minutes until the positive controls developed a blue-green 
color. The absorbance was read on a microplate ELISA reader 
(Bio-Rad Benchmark Plus, Hercules, CA) at 410 nm. After 
assay validation (absorbance values of control positive serum 
greater than or equal to five times above values of control neg-
ative serum), cut-off values were set at 2.1 times the average 
absorbance readings for duplicate negative control sera. 
   Anti-YFV  IgG  antibody  detection.     The protocol for GAC-
ELISA  22   was nearly the same as that used for MAC-ELISA 
with a few modifications. Microtiter plates were coated with 
100 μL of a 1:200 dilution of affinity-purified goat anti-human 
IgG (Jackson Immuno Research Laboratories, Inc., West Grove, 
PA) in carbonate buffer (pH 9.6) and incubated overnight at 
4°C before being washed with PBS containing 0.05% Tween 
20 (PBS-T; pH 7.4). After washing, the plates were blocked 
with 200 μL PBS containing 10% non-fat dry milk (NFDM) 
and then incubated for 1 hour at RT. The plates were again 
washed in PBS-T as before. Patient serum (50 μL diluted 1:50 
in PBS containing 1% NFDM) was added in duplicate to the 
microtiter wells and incubated at 37°C for 1 hour (positive and 
negative control sera were included). After washing, 50 μL YF 
antigen diluted 1:32 in PBS/1% NFDM (16 HA units) were 
added to each microwell and incubated at 37°C for 1 hour. 
After washing, 25 μL horseradish peroxidase-conjugated 
anti-flavivirus monoclonal antibody 6BC1-1 (CDC) diluted 
1:13,000 in PBS/1% NFDM were added to each well. After 
another incubation at 37°C for 30 minutes, the plates were 
washed six times in PBS-T and then allowed to develop with 
100 μL freshly prepared ABTS solution in H  2 0 2   diluted 1:1. 
The reaction was allowed to proceed in the dark at RT for 
30–60 minutes until the positive controls developed a blue-
green color. Absorbance was read on the microplate ELISA 
reader at 410 nm. After assay validation as described above, 
cut-off values were set at two times the average absorbance 
readings for duplicate negative control sera. An index value 
was calculated by dividing the second sample (after vaccina-
tion) absorbance by the first sample (prior vaccination) absor-
bance for comparing levels of IgG antibodies in both samples. 
Results were interpreted as follows: < 0.9 (negative); 0.9–1.1 
(inconclusive), and > 1.1 (positive; index = sample after vaccine 
absorbance/sample prior vaccine absorbance). 742 MELO AND OTHERS
   Indirect  anti-YFV  IgG  ELISA.     Serum samples were also 
tested using the protocol adapted from Kuno and others.  23   In 
brief, microtiter plates were coated with 100 μL of a 1:32 dilution 
of YF antigen in carbonate buffer (pH 9.6) and incubated 
overnight at 4°C. Before use, the plates were washed four 
times with PBS-T, blocked with 200 μL PBS/10% NFDM, and 
then, incubated for 1 hour at RT. After washing, 50 μL patient 
sera diluted 1:50 in PBS/1% NFDM were added in duplicate 
to the plate wells and incubated at 37°C for 1 hour (positive 
and negative control sera were also tested). After washing, 
25  μL affinity-purified goat anti-human IgG conjugated 
with horseradish peroxidase (Zymed Laboratories Inc., San 
Francisco, CA) diluted 1:1,000 in PBS/1% NFDM were added 
to each well, and the plates were incubated at 37°C for 1 hour. 
The plates were then washed six times in PBS-T and incubated 
with 100 μL freshly prepared tetramethylbenzidine (TMB; BD 
Biosciences Pharmingen, San Diego, CA) substrate solution in 
the dark at RT for 30–60 minutes until the positive controls 
developed color. The absorbance was read on a microplate 
ELISA reader at 450 nm (630-nm reference filter). After 
assay validation as described above, cut-off values were set at 
2.1, which was two times the average absorbance readings of 
duplicate negative control sera after subtraction of background 
readings from a blank control well. 
   PRNT.   The PRNT was performed using a modified protocol 
of Morens and others.  24   Samples collected from the same 
volunteer were processed together in the same set of tests. 
Tests were carried out on Vero cells that had been seeded 
at a density of 300,000 cells/mL and grown in MEM/10% 
FBS in 24-well microplates (0.5 mL/well) for 24 hour before 
assay. Human serum samples from YF-17DD vaccinees were 
inactivated for 30 minutes at 56°C before being diluted in 
MEM. The assay for the detection of YFV neutralizing 
antibodies was performed after serial twofold dilution of 
serum (1:20 to 1:2,560) into 96-well microtiter plates and 
addition of 30 PFU of challenge virus (17DD YFV strain) to 
all wells. After incubation at 37°C in a 5% CO  2   atmosphere for 
1 hour, the medium of the 24-well microplates was discarded, 
and 50 μL each dilution of the mixture serum/virus were 
inoculated in triplicate. The plates were then incubated at 
37°C in 5% CO  2   for 1 hour to allow virus adsorption. After 
incubation, the cells were overlaid with 0.5 mL MEM medium 
containing 10% FBS, 1% penicillin/streptomycin, and 2.7% 
carboxymethylcellulose. After incubation for 6–7 days at 37°C 
in 5% CO  2  , the cell monolayer was fixed with formalin and 
stained with crystal violet, and the plaques were counted. 
Standard sera of known antibody content were included in 
each set of tests (negative < 1:20 and positive = 1:320). The 
50% endpoint dilution of each serum, corresponding to the 
dilution at which 50% of the wells were completely protected 
from infection, was determined according to the Reed–Muench 
method.  26   Plaque neutralization titers were calculated as the 
highest dilution of antibody reducing 50% of the plaques of 
input virus. All PRNT assays were completed by the same 
technician using the same standard assay procedure. 
   Seroconversion.    To  document  YF-17DD  seroconversion, 
the antibody profile obtained at the beginning of the study 
(before vaccination) was compared with the antibody status 
determined in subsequent serum samples. First, second, and 
third serum samples collected from volunteers were analyzed 
by PRNT; first and second samples were analyzed by ELISA 
anti-YFV IgM, anti-YFV IgG, and anti-dengue IgG. 
   Database.     The study data were integrated into a customized 
digital database that included a questionnaire, serological 
and research results, and the respective inventories of cryopre-
served samples. This FileMaker-based database has been pro-
grammed and hosted by the Department of Virology, Centro de 
Pesquisas Aggeu Magalhães (CPqAM)-Fiocruz and has been 
used for cohort management and patient/sample tracking.  27   
   Retrospective  study.     We also performed a retrospective 
analysis of a random sample of individuals who had been 
vaccinated 5 (  N   = 20) or 10 (  N   = 20) years ago with the 17DD 
vaccine. These individuals were randomly selected from the 
ANVISA YF vaccine database, contacted by telephone, and 
invited to participate of the study in 2007. The objective was 
to investigate the levels of YF neutralizing antibodies at 5 and 
10 years after immunization. A single blood sample was 
collected from each participant for analysis of YF antibody 
titers by PRNT as described above; the capture anti-YFV 
IgG ELISA was also performed in these samples. Statistical 
analyses were conducted as described below. 
   Statistical  analysis.     Statistical analyses were performed with 
GraphPad Prism version 4.0 for Mac (GraphPad Software, Inc.) 
and the R program (R Foundation for Statistical Computing). 
Antibody titers after vaccination were analyzed using the 
general linear model Y  ijk   =  μ + P  i   + D  j   + V k +   e ijk  , where Y is the 
response variable, μ is the general average of the experiment, 
P is the individual effect of collaborators, D is the presence of 
antibody against DENV before and after YF vaccination, V is 
the effect of the period between YF vaccination and moment 
of YF antibody titer evaluation included as a covariate, and e  ijk  
is the residual effect normal independent distribution (NID; 
0,  σ  2  ; average 0 and constant variance). The time between 
vaccination (5 and 10 years) and serum neutralization test in 
the retrospective study was analyzed using the general linear 
model Yi = m + Ti + e  i , where Y is the response variable, m is the 
general average of the experiment, and T is the time between 
vaccination and serum neutralization test. A non-parametric 
Wilcoxon test was used to compare the YF IgG and YF PRNT 
indices between positive and negative dengue patients. Non-
linear regression of the YF IgG and YF PRNT indices as a 
function of time post-vaccination in days was performed by a 
locally weighted polynomial regression (lowess) implemented 
by the R function plot.smooth.line. 
    RESULTS 
  Volunteer  recruitment.     The recruitment of vaccination 
candidates for the prospective study began in September 
2005. The volunteers consisted of healthy YFV vaccine-naïve 
individuals living in Recife, Brazil, who were 10 years of age 
or older and were traveling to regions of Brazil and/or abroad 
where YF vaccination is recommended. Recruitment ended in 
March 2007. 
   Study  cohort  characteristics.     From September 2005 to 
August 2009, a total of 951 blood samples from 260 YF-17DD 
vaccinated volunteers was obtained and assayed. Serum, 
plasma, and PBMC samples were stored. A total of 3,200 
PBMC sample vials (4 × 10  6   or 8 × 10  6   cells per vial) was 
cryopreserved for further studies. Of the 260 initial cohort 
volunteers, 22 (8.5%) were excluded from the study, because 
it was not possible obtain follow-up samples. Thus, the final 
cohort consisted of 238 subjects who each provided a set of 
three to six consecutive samples, with an average of four blood 743 17DD YELLOW FEVER VACCINE COHORT
samples per subject. In general, the vaccine was well-tolerated, 
and there were no reports of severe adverse events. Only three 
participants (29, 34, and 57 years old) reported fever, and one 
subject (43 years old) reported pain in the injection site. The 
age range of the volunteers was 14–79 years (median age = 32 
years); 86 (36.1%) were female, and 152 (63.9%) were male. 
There was only one volunteer younger than 15 years and six 
volunteers older than 70 years; the majority of the volunteers 
were older than 17 years of age. 
      Baseline sampling: anti-YFV IgG and anti-DENV IgG.    To  
confirm that the volunteers were being immunized for the first 
time, all samples collected before immunization were tested for 
anti-YFV IgG antibodies using both IgG ELISA techniques, 
and none of the 260 serum samples obtained before vaccination 
revealed any anti-YFV antibody. To determine whether pre-
vious exposure to dengue had a significant effect on the YFV 
vaccination results, we investigated the presence of anti-
dengue IgG in this cohort. The serological tests performed 
on the pre-vaccination samples revealed that 82% (195/238) 
of the volunteers were positive for anti-dengue antibodies. 
Interestingly, among the 43 anti-dengue negative subjects, 21% 
(9/43) presented anti-dengue IgG in the next blood sample, 
which was taken approximately 1 month after immunization. 
Two other anti-dengue IgG-negative individuals seroconverted 
later, one 2 months later and another subject 1 year later. 
None of these individuals reported having had dengue fever; 
nevertheless, it is known that asymptomatic dengue cases are 
common, and in this period, dengue epidemics have occurred 
in this region. It is not clear if this seroconversion was caused 
by dengue infection or cross-reaction between anti-YFV 
antibodies and the DENV epitopes. At the end of the study 
4 years later, 13.4% of the volunteers (32/238) remained 
negative for DENV. In summary, 86.6% (206/238) of subjects 
were considered dengue IgG-positive, and in 13.4% (32/238) 
of the subjects, anti-dengue IgG was not detected. 
      Evaluation by ELISA of antibody responses to YF-17DD 
vaccination.     YFV IgM and IgG antibody detection was 
performed on 498 first and second serum samples. Of the 238 
serum samples obtained after vaccination, anti-YFV IgM was 
detected in 70.6% (168/238). Among the 70 anti-YFV IgM-
negative subjects, 18.6% (13/70) and 81.4% (57/70) of sub-
jects were negative between days 27 < 60 and 60 < 348 for 
anti-YFV IgM, respectively (  Table 1  ). It was observed that 
91.5% (64/70) of the anti-YFV IgM-negative volunteers had 
previously been exposed to DENV, whereas 83.4% (140/168) 
of the anti-YFV IgM-positive subjects had been exposed 
to dengue; however, this difference was not statistically 
significant. Anti-YFV IgG assays, both capture and indirect 
ELISA, showed that 98.3% (234/238) of subjects were positive 
for IgG, whereas ~1.7% (4/238) remained negative (  Table 1  ). 
Three of four seronegative volunteers were also YFV-IgM–
negative (on days 100, 106, and 348). Despite all four YFV IgG-
negative subjects having detectable anti-dengue IgG, the YFV 
IgG index was higher in all points of the curve in anti-dengue 
IgG-positive than anti-dengue negative individuals (  Figure 2  ). 
The difference was statistically significant with   P   < 0.001. 
            Female volunteers had a lower seroconversion rate for IgM 
than did males (64% versus 74%). However, this difference 
was not statistically significant. 
      Evaluation by PRNT of neutralizing antibody responses 
to YF-17DD vaccination.     For the analysis of the protective 
immune response after vaccination, the PRNT is currently 
considered the gold standard.  28   PRNT measures antibod-
ies against neutralizing epitopes, whereas ELISA measures 
binding antibody against non-neutralizing and neutralizing 
epitopes. The main difference is that PRNT determines anti-
body functionality and is correlated with protective immu-
nity. This assay is more sensitive and the most specific of the 
serologic tests.  29,  30   Therefore, in addition to the IgM and IgG 
ELISAs, we also performed PRNT on samples collected 
before and after vaccination. 
  None of the samples collected before vaccination showed 
neutralizing antibodies to YFV, including those samples with 
anti-DENV antibodies. Analysis of the prospective cohort 
showed that 100% of the individuals developed a protective 
humoral immune response, which was defined as a PRNT titer 
of ≥ 1:20, including the three individuals who did not produce 
detectable amounts of anti-YFV IgG or IgM. Post-vaccination 
PRNT values fluctuated during the first 3 months. The higher 
neutralization titer found had a geometric mean titer (GMT) 
of 1,810 (95% confidence interval [CI] = 744–3096), and the 
lowest neutralizing titer found had a GMT of 452 (95% CI = 
160–640). A more detailed analysis of the PRNT results is 
shown in   Table 2  . In the 238 serum samples analyzed, those 
from subjects without antibodies to DENV had a higher 
neutralizing titer against YFV (GMT = 884) than those with 
 Table 1 
    Detection of YFV-specific IgM and IgG antibodies according to the 
time of sample collection (  N   = 238)   
Number of days since 
immunization
IgM antibodies IgG antibodies
Negative (%) Positive (%) Negative (%) Positive (%)
27–40 6 (12.8) 41 (87.2) 0 (0) 47 (100)
40–60 7 (14) 43 (86) 1 (2) 49 (98)
60–80 15 (35.7) 27 (64.3) 0 (0) 42 (100)
80–100 25 (36.2) 44 (63.8) 0 (0) 69 (100)
100–349 17 (56.7) 13 (43.3) 3 (10) 27 (90)
Total 70 (29.4) 168 (70.6) 4 (1.7) 234 (98.3)
 Figure 2.        Comparison of YFV IgG index between anti-dengue–
positive and -negative individuals after YF-17DD vaccination 
(  N   = 238).   744 MELO AND OTHERS
anti-DENV IgG antibodies (GMT = 781). However,   Figure 3   
shows that this difference was not significant. 
          Retrospective  study.     Individuals who had been immunized 
5 or 10 years earlier for YFV were randomly selected from 
the ANVISA immunization records. The 40 individuals who 
agreed to participate had received YF-17DD either 5 (  N   = 
20) or 10 years ago (  N   = 20). The age of the volunteers ranged 
from 16 to 59 years (median age = 42.5 years; standard 
deviation [SD] = 11.5) for the 5-year group and from 30 to 83 
years (median age = 50.5; SD = 15.4) for the 10-year group. Of 
the 40 volunteers, 28 (70%) were female; the overall age range 
was 16–83 years (median = 46 years). These samples were 
submitted to the capture anti-YFV IgG ELISA; 60% (12/20) 
and 55% (11/20) of the individuals immunized were anti-
YFV IgG-positive 5 or 10 years post-vaccination, respectively. 
However, neutralizing antibodies against YFV were detected 
in all 40 subjects. In the 5-year post-vaccination group, the 
PRNT titers varied from 40 to 640, with a GMT of 149 (95% 
CI = 124–328), and in the 10-year post-vaccination group, they 
showed a further decrease in titer, with a GMT of 113 (95% 
CI = 102–188) and a range of titers from 20 to 320 (  Figure 4  ). 
The anti-YFV IgG-negative samples were found mainly in 
those individuals presenting PRNT titers from 1:20 to 1:80; 
25% (5/20) of the individuals had PRNT titers below 100 at 
5 years post-immunization, whereas 35% (7/20) had presented 
a titer below 100 at 10 years after immunization. This differ-
ence was not significant (data not shown). The ELISA results 
have shown that PRNT is a more sensitive assay, and they 
emphasize the importance of using this test when measuring 
protective immunity. 
     DISCUSSION 
  In the present study, we have established and analyzed the 
immunologic responses of a cohort of individuals living in 
Recife, Brazil, that had been vaccinated against YF with the 
17DD vaccine. It is known that both the 17D and 17DD YFV 
vaccines induce long-lasting immunity in nearly 100% of indi-
viduals vaccinated with a single dose.  2   The  immunological 
profile of the 17DD vaccine has always been assumed to be 
identical to that of the 17D vaccine; however, a formal demon-
stration of the immunological profile of 17DD has been lack-
ing in the scientific literature. In addition, it is not known if 
 Table 2 
    Follow-up of neutralization titer after YF-17DD vaccination (2005–2009)   
Months post-vaccination Number of samples (serum) Geometric mean titer 95% CI Median PRNT titer of reactive sera PRNT titer (minimum to maximum)
1–2 94 912 966–1,230 1,280 160–2,560
2–3 75 829 848–1,087 640 80–2,560
3–4 62 626 677–985 640 160–2,560
4–7 9 941 576–1,877 1,280 160–2,560
7–8 4 1,810 744–3,096 1,920 1,280–2,560
8–9 7 1,280 721–2,205 1,280 640–2,560
9–10 8 1,280 811–2,309 1,280 320–2,560
10–11 32 1,174 1,138–1,712 1,280 160–2,560
11–12 31 1,024 971–1,517 1,280 160–2,560
12–13 41 1,045 1036–1,540 1,280 160–2,560
13–14 24 1,046 941–1,526 1,280 160–2,560
14–15 12 678 451–1,523 640 160–2,560
15–16 4 761 291–1,309 640 640–1,280
16–17 4 452 139–902 640 160–640
 Figure 3.        Comparison of neutralization antibody titers between 
anti-dengue–positive and -negative individuals after YF-17DD vacci-
nation (  N   =  238).    
 Figure 4.        Neutralization antibody titers 5 and 10 years after 
YF-17DD vaccination (  N   =  40).    745 17DD YELLOW FEVER VACCINE COHORT
previous infection by dengue would interfere with the 17DD 
vaccine response. In our prospective study, all volunteers had 
neutralizing antibodies at 1 month after vaccination (GMT = 
912); in the retrospective study, the same was true at 10 years 
post-vaccination (GMT = 113), although at much lower titers. 
These results are similar to those previously obtained with the 
17D vaccine  31   and suggest that a single dose of the YF-17DD 
vaccine may provide protection from wild-type YFV infec-
tion for at least 10 years, which is consistent with the World 
Health Organization (WHO) recommendation for interna-
tional travel to YF-endemic areas. The minimum PRNT titer 
necessary guarantee protection is not clear, and because 35% 
of the individuals presented titers below 1:100 after 10 years 
post-vaccination, the WHO recommendation to repeat YFV 
immunization every 10 years is very reasonable.  29,  32  
  The YF vaccine is regarded as one of the safest attenu-
ated virus vaccines with few adverse reactions; nevertheless, 
fatal cases associated with YF-17DD vaccine in Brazil were 
reported during a period of intensified vaccination in the 
country.  15   Most of these adverse reaction cases were in elderly 
and immune-compromised individuals. Indeed, a study from 
the United States reported higher frequency of severe adverse 
events in elderly people, with those older than 75 years hav-
ing a risk 12 times higher than that of young adults.  18   It was 
not the intent of this study to determine the frequency of 
17DD adverse reactions given the small sample size of our YF 
cohort; however, four subjects (1.7%) reported fever or dis-
comfort at the injection site. The precise frequency of severe 
adverse effects remains uncertain; according to several stud-
ies, it may be approximately 1 in 10,000, with a lethality rate of 
less than 1 in 100,000.  2   In contrast to other live attenuated vac-
cines, the 17DD vaccine is quite safe. The neurologic disorders 
after measles–mumps–rubella and oral poliovirus vaccines are 
reported at the rate of 1 case per 2.5 million  33   and 0.06 per 
100,000  34   vaccinees, respectively. Despite the fact that the YF 
vaccines are considered effective and very safe, their use is not 
recommended in some circumstances, such as breastfeeding, 
immunological diseases, and allergies to egg products among 
others, and it is important to develop a new YF vaccine using 
new production strategies to have less adverse events. 
  Enzyme immunoassay has become the method of choice for 
rapid serodiagnosis of virus infections by detection of specific 
IgM antibodies and has been frequently applied in a quantita-
tive assay format to monitor immune response to vaccines.  35  
Serologic diagnosis is generally accomplished by measure-
ment of IgM antibodies by ELISA, hemagglutination inhi-
bition (HI), and neutralization.  2   Here, we have analyzed the 
humoral immune response against YFV after vaccination over 
long and short periods of time. In the 238 individuals whose 
serum samples were analyzed by MAC-ELISA, anti-YFV IgM 
was detected in 70.6% of cases. Studies have shown that a sig-
nificant amount of IgM antibody can be present as long as 60  30  
and 82 days  36   after primary vaccination against YF-17D. In 
some individuals, anti-YFV IgM can persist for 100–120 days 
or more.  2,  37  Here, we observed that anti-YFV IgM was detected 
in 15 samples collected 100 days after vaccination. In a study 
of 17 naïve individuals vaccinated with YF-17D reported by 
Vazquez and others,  35   it was found that 94% seroconverted, 
and no cross-reaction with dengue antigen was observed using 
the MAC-ELISA test. In another study, Lhuillier and others  37  
found high specificity of IgM antibodies response in individu-
als with YF infections. The lack of detection of IgM in ~30% 
of the vaccinees enrolled in this study is most likely because 
of the time of the blood collection, which was typically more 
than 30 days post-vaccination. However, it is known that, in 
secondary flavivirus infections, the level of IgM is lower than 
in primary infection, and in many cases, it can be undetect-
able.  38   However, it could be also considered as a false negative 
because of the low sensitivity of MAC-ELISA to detect IgM. 
The YFV-IgG seroconversion was detected in 98.3% (234/238) 
of the cohort volunteers, and the four vaccinees that did not 
seroconvert were anti-dengue IgG-positive. Nevertheless, 
these four individuals showed significant PRNTs. 
 YFV and DENV share epitopes and therefore, induce cross-
reactive antibodies, which often cause difficulties in differen-
tially diagnosing flavivirus infections.  39   There is a clear chance 
of obtaining false-positive results because of antibodies cross-
reacting with similar epitopes found in other flaviviruses 
(resulting from either natural infection or vaccination).  28  
  In Brazil, several arboviruses (Mayaro, Oropouche, YF) 
have been responsible for outbreaks of acute febrile illness 
in the Amazon region and on the Central Plateau.  4   In addi-
tion, one report has also suggested presence of Saint Louis 
Encephalitis virus. However, the only arbovírus detected in 
the northeastern region of Brazil for the past 30 years was 
DENV. For the past 25 years, dengue fever has been consid-
ered a serious public health problem in Brazil. The northeast-
ern region of Brazil is one of the most severely affected areas 
in the country,  21   and in the case of dengue, Pernambuco is the 
second most-affected state in this region, with an incidence 
rate ranging from 134 to 1,438 per 100,000 inhabitants (in 1995 
and 2002, respectively). In Recife, the capital of Pernambuco, 
the dengue incidence rate ranged from 28 to 2,378 per 100,000 
inhabitants in the same period.  38   From 2003 to 2010, Recife 
experienced a low endemic period, with an average of 37 cases 
per 100,000 inhabitants, despite the presence of three DENV 
serotypes (DENV-1, -2, and -3). This decline was probably 
caused by either an intensification in the vector control mea-
sures or a high prevalence of dengue immunity in the popula-
tion.  40   A population-based household dengue survey carried 
out in three distinct areas of the city of Recife between 2005 
and 2006 showed a high dengue seroprevalence in the region, 
with prevalences of 91.1%, 87.4%, and 74.3%, respectively, in 
deprived, intermediate, and high socio-economic areas.  41  Thus, 
the presence of dengue IgG antibodies in 86.6% of subjects 
enrolled in the YF cohort is consistent with these data. 
  ELISA assays for YF and DENV had a high cross-reactivity, 
resulting in rises of IgG titers in secondary infections.  39   It was 
found that the YFV IgG was higher in volunteers that had pre-
viously been exposed to DENV. Reports presented by other 
researchers show a higher cross-reactivity between these fla-
vivirus.  28,  30   Because PRNT has been proposed as the assay of 
choice for differentiating YFV and DENV infections,  39   all 
serum samples were also subjected to the neutralization test. 
Despite that the other studies have shown that DENV-naive 
and DENV-exposed subjects developed different neutral-
izing titers against YFV,  42,  43   this profile was not found in our 
analysis. 
  Gender differences in vaccine immunogenicity have been 
found in other studies  44,  45   and were considered in the present 
study. Anti-YFV IgM antibodies detected by ELISA showed 
a gender-specific immune response; nevertheless, slightly 
higher neutralizing titers in the PRNT were found in males, 
but this difference was not statistically significant. The reason 746 MELO AND OTHERS
for stronger immune response in men than in women after YF 
vaccination remains unclear, although this phenomenon has 
been reported before.  28  
  In conclusion, our analysis of the immune response to YF 
immunization with 17DD yielded an immunological profile 
identical to that of the 17D vaccine. 17DD was showed to 
be highly immunogenic, producing 100% seroconversion by 
PRNT and long-term persistence of neutralizing YFV anti-
bodies 10 years after vaccination. Additionally, the immuno-
genicity does not seem to be significantly affected by previous 
exposure to natural dengue infection. 
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